NR 566

What is the most common organism for CAP? streptococcus pneumoniae what are the causative organisms for CAP -streptococcus pneumoniae -atypical bacteria (mycoplasma pneumoniae): older and young adults -viruses (RSV, influenza) smoker type of aquired CAP H. influenzae Cystic fibrosis acquired CAP pseudomonas aerguinosa immunocompromised CAP pneumocystitis carini first line of treatment for CAP healthy adults amoxicillin (PCN), doxycycline, azithromycin what to give second if first l...

Beta-lactam antibiotics Penicillins Cephalosporins Carbapenems Monobactams Before Liraglutide, Ensure pt.... Can administer injections Ongoing monitoring for Liraglutide Hgb, Triglycerides, s/s of cholecyctitis, pancretitis, depression, and SI Pt. teaching for Naltrexone Can precipitate withdrawal. Monitor for s/s of liver injury Naltrexone/Bupropion (Contrave) will NOT cause Withdrawal symptoms (for weightloss) Baseline data/monitoring for Naltrexone/Bupropion (Contrave) Blood glu...

Albuterol -increases levels of digoxin -safe if children -first line therapy Etidronate (Didronel) Bisphosphonates -90 day half life -preg cat B reduces bone reabsorption TX: low bone density, d/t cystic fibrosis, pagets disease (monitor xrays and labs), heterotropic ossification, hip replacement, spinal cord injury CI: entercolitis

Bioavailability of bisphosphonate drugs and appropriate patient education Histamine2 blocking agents double alendronate bioavailability, but the impact is unknown. Aspirin may decrease the bioavailability of tiludronate by up to 50% when taken 2 hours after the tiludronate. Although indomethacin increases the bioavailability of tiludronate by 2- to 4-fold, the bioavailability is not significantly altered by diclofenac; therefore, each NSAID must be considered individually.

Which pathogen is highly associated with CAP in the general population? A. Haemophilus influenza B. Pseudomonas Aeruginosa C. Streptococcus pneumonia D. None of these C. Streptococcus pneumonia

NR 566 Final Exam – Advanced Pharmacology Study Guide - Chamberlain NR 566 Final Exam – Advanced Pharmacology Study Guide - Chamberlain NR 566 Final Exam – Advanced Pharmacology Study Guide - Chamberlain

Chlamydia (Among Adolescents and Adults) Treatment - ANSWER>>Doxycycline 100 mg Orally BID for 7 day **Alternative therapy: - Azithromycin 1g Orally in a single dose - Levofloxacin 500 mg orally daily for 7 days Uncomplicated gonococcal urethritis Treatment - ANSWER>>Chlamydial infection is excluded: Ceftriaxone 500 mg IM single dose If Chlamydial infection has not been excluded: - Ceftriaxone 500 mg IM single dose - Doxycycline 100 mg Orally BID for 7 day

NR 566 FINAL EXAM (2 LATEST VERSIONS ) / NR566 FINAL EXAM 300 QUESTIONS & ANSWERS / ADVANCED PHARMACOLOGY FOR CARE OF FAMILY|ALREADY GRADED A+

NR 566 FINAL EXAM (2 LATEST VERSIONS ) / NR566 FINAL EXAM 300 QUESTIONS & ANSWERS / ADVANCED PHARMACOLOGY FOR CARE OF FAMILY|ALREADY GRADED A+

NR 566 / NR566 Advanced Pharmacology Care of the Family Midterm Review Quiz bank | LATEST, Questions and Verified Answers | Chamberlain College